Publications by authors named "L Hogenboom"
Article Synopsis
- Serum neurofilament light (sNfL) serves as a biomarker for neuro-axonal damage in multiple sclerosis (MS) but its clinical usage is still limited; this study assessed how its implementation affects clinical decisions at the MS Center Amsterdam.
- Over the study period (August 2021-December 2022), sNfL was evaluated in various contexts, with a notable change in clinical decisions in 19.3% of cases, especially when assessing new symptoms or when higher sNfL levels were present.
- The findings suggest that integrating sNfL into clinical practice improved decision-making certainty and potentially adjusted expectations regarding MRI activity, indicating its potential value in patient care while calling for further research
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.
Mult Scler Relat Disord
November 2024
Introduction: Ocrelizumab (OCR) is a highly effective treatment of multiple sclerosis (MS), and B cell repopulation profiles suggest that it might be used as an immune reconstitution therapy. However, data on disease recurrence after stopping treatment with OCR are scarce. Our objective was to evaluate the recurrence of disease activity after OCR discontinuation.
View Article and Find Full Text PDFA personalized approach for anti-CD20 therapies in multiple sclerosis.
Mult Scler Relat Disord
November 2024
Article Synopsis
- * Ongoing randomized controlled trials are exploring different approaches to dosing ocrelizumab, including higher doses, personalized B-cell dosing, and potential treatment discontinuation.
- * The proposed roadmap aims to use trial outcomes to improve understanding and effectiveness of anti-CD20 therapies, addressing existing knowledge gaps in MS treatment.
Background: Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell subsets are differentially repopulated after different dosing intervals and whether these subsets relate to clinical efficacy.
Methods: We performed high-dimensional single-cell characterization of the peripheral immune landscape of patients with MS after standard (SID; n = 43) or extended interval dosing (EID; n = 37) of ocrelizumab and in non-ocrelizumab-treated (control group, CG; n = 28) patients with MS, using mass cytometry by time of flight (CyTOF).
Background: The majority of patients with multiple sclerosis on ocrelizumab have B-cell depletion after standard interval dosing of 26 weeks. With B-cell-guided dosing patients receive their next dose when B-cell repopulation occurs. Prediction of B-cell repopulation using ocrelizumab concentrations could aid in personalising treatment regimes.
View Article and Find Full Text PDF